-
Global dosing hold in fitusiran trials initiated by Sanofi Genzyme to investigate new adverse events
A joint statement of the World Federation of Hemophilia (WFH), European Haemophilia Consortium (EHC) and National Hemophilia Foundation (NHF) November 6, 2020 – The WFH,...
-
A Patient Videoconference on Inhibitors & New Novel Therapies – Answering Your Questions!
On November 2, 2020, the CHS held a live educational videoconference aimed to improve the understanding of FVIII/FIX inhibitors and treatment options, with a...
-
Access to Innovative and Curatives Therapies – NRBDO virtual conference
NOVEMBER 5-7 Many innovative and curative therapies are coming to market for rare blood disorders, but will they be available to Canadian patients? What is...
-
COVID-19 updates
Access the most updated information regarding COVID-19 and inherited bleeding disorders: www.hemophilia.ca/covid-19
-
WFH Advisory: availability of desmopressin
WFH Advisory: availability of desmopressin pending re-start of intranasal desmopressin manufacture